Assessment of the Anterior Chamber Flare and Macular Thickness in Patients Treated with Topical Antiglaucomatous Drugs

作者：Selen Firat; Tekeli Oya^*; Yanik Ozge

来源：Journal of Ocular Pharmacology and Therapeutics, 2017, 33(3): 170-175.

DOI：10.1089/jop.2016.0128

• central macular thickness
• flare
• glaucoma
• macular edema
• prostaglandins

Purpose: To determine the changes in the anterior chamber flare and central macular thickness (CMT) under topical antiglaucomatous therapy.
Methods: This study included 121 eyes of 73 patients and 36 eyes of 18 controls. Glaucoma patients were divided into 3 groups (timolol maleate, latanoprost, and bimatoprost). Control eyes did not receive any medications. Flare and CMT measurements were performed at baseline and follow-up visits (15th day, and 1st, 3rd, 6th, and 12th month).
Results: Statistically significant increases were detected in the flare values in the bimatoprost and latanoprost groups (P < 0.001, P = 0.011, respectively). Significant increases were also found in CMT values measured in these 2 groups (P < 0.001, P = 0.002, respectively). However, increased flare and CMT values were not clinically manifested as uveitis and macular edema. Flare and CMT values did not change statistically in the timolol maleate and control groups.
Conclusions: Although the use of prostaglandin (PG) analogs was found to be associated with increased flare and CMT, these increases were not clinically significant. PG analog monotherapy may be safely and effectively used in the treatment of glaucoma.